N-Acetylcysteine Amide

Phase 3Small molecule

NNacuity Pharmaceuticals, Inc.

N-Acetylcysteine Amide is one of 5 small molecule programs targeting Cystinosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CystinosisActive, not recruiting

Retinitis Pigmentosa (RP)Not yet recruiting

CystinosisPreclinical

Active, not recruiting

Retinitis Pigmentosa (RP)Phase 3

Not yet recruiting

Competition

Competitive Landscape

4 competitors in Retinitis Pigmentosa (RP)

#DrugCompanyPhaseTrials

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Phase 3

1 2

NPI-001

NNacuity Pharmaceuticals, Inc.

Phase 3

1 3

Intravitreal Injection of Ultevursen

LLaboratoires Thea

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Not yet recruiting

Retinitis Pigmentosa (RP)

NCT07290530

Clinical

Trials by Indication[1]

Retinitis Pigmentosa (RP)1 trial

A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome

Not yet recruiting·NNacuity Pharmaceuticals, Inc.·Phase 3·NCT07290530·80 enrolled

Cystinosis1 trial

A Phase 1/2 Pharmacokinetic and Pharmacodynamic Study of NPI-001 Oral Solution Compared to Cysteamine Bitartrate in Cystinosis Patients

Active, not recruiting·NNacuity Pharmaceuticals, Inc.·Preclinical·NCT05994534·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for N-Acetylcysteine Amide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — N-Acetylcysteine Amide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for N-Acetylcysteine Amide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nacuity Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNacuity Pharmaceuticals, Inc.

N-Acetylcysteine Amide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Retinitis Pigmentosa (RP)1 trial

Cystinosis1 trial

References

Drug Info

Quick Facts

Related News